Description: FASENRA® (benralizumab) for treatment of severe eosinophilic asthma in patients 6 years or older. Learn more about FASENRA studies in severe asthma.
FASENRA is indicated as an add-on maintenance treatment of patients 12 years and older with severe eosinophilic asthma.
FASENRA is not indicated for treatment of other eosinophilic conditions or for the relief of acute bronchospasm or status asthmaticus.
51% reduction in the annual asthma exacerbation rate was observed in patients treated with FASENRA + standard of care (SOC) (n=267) vs placebo + SOC (n=267) (0.74 vs 1.52, P <0.0001). 1,2